From: Michael Owings [Michael.Owings@phaseforward.com]
Sent: Monday, January 03, 2005 4:02 PM
To: 'fdadockets@oc.fda.gov'
Cc: Alan Pollack
Subject: Docket: 2004D-0440: Phase Forward Comments

Please find attached our comments to Docket 2004D-0440, Guidance for Industry: Computerized Systems Used in Clinical Trials, September 2004.



Regards, Michael Owings







Michael Owings
Vice President, Quality and Regulatory Compliance
Phase Forward
880 Winter Street
Waltham, MA 02451
USA

T: 781.902.4456
F: 781.890.4848
www.phaseforward.com



                                    



This message contains privileged and confidential information intended only for the use of the addressee(s) named above. If you are not the intended recipient of this message, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination or copying of this message is strictly prohibited. If you have received this message in error, please immediately notify the sender by return electronic mail and delete the original message without retaining a copy.